NCT02414945View on ClinicalTrials.gov

TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

May 15, 2015

Primary Completion Date

October 31, 2020

Study Completion Date

October 31, 2020

Conditions
Pleural Mesothelioma
Interventions
DRUG

Cyclophosphamide

DRUG

Fludarabine

BIOLOGICAL

Autologous tumor infiltrating lymphocytes (TILs)

BIOLOGICAL

Interleukin-2

Trial Locations (1)

M5G 2M9

Princess Margaret Cancer Centre, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER

NCT02414945 - TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients | Biotech Hunter | Biotech Hunter